At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,091 enrolled
Drug / intervention
Panitumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
In Brief
An observational study evaluating Panitumumab for Advanced or Recurrent Colorectal Cancer. Completed, enrolled 3,091 participants.
Detailed Summary
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease, infusion reactions, electrolyte abnormalities, and cardiac disorders.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Recurrent Colorectal Cancer
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
Primary CompletionJul 2012
First PostedMar 2014
TodayJul 2026
First PostedMar 18, 2014
Enrollment StartJun 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.3 years ago
Interventions
Panitumumabdrug
Panitumumab for intravenous infusion